Trinity Biotech plc (TRIB) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Apr 30, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the TRIB SEC filings page.
Trinity Biotech plc (TRIB) reported $43.8M in revenue for fiscal year 2025, down 28.9% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
A reported profit in FY2025 masks a business still consuming cash, with liabilities overwhelming assets and short-term liquidity compressed.
The shift from a net loss of$31.2M in FY2024 to net income of$1.9M did not translate into cash: operating cash flow was-$5.9M and free cash flow was-$6.0M . This earnings-to-cash gap means the accounting improvement was not matched by cash-generating operations, so it does not yet represent a complete operating turnaround.
The balance sheet is structurally strained:
Revenue fell from
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Trinity Biotech plc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Trinity Biotech plc held $5.1M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $5.9M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Trinity Biotech plc scores 30/100 among other emerging companies.
Trinity Biotech plc had 374M shares outstanding at the end of fiscal year 2025, against 359M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Trinity Biotech plc scores 19/100 among other emerging companies.
Not available for Trinity Biotech plc, and counted as zero in the overall score.
Trinity Biotech plc reported revenue of $43.8M in fiscal year 2025, against $61.6M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Trinity Biotech plc scores 27/100 among other emerging companies.
Trinity Biotech plc's operations used $5.9M of cash in fiscal year 2025, against $4.2M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Trinity Biotech plc scores 72/100 among other emerging companies.
Trinity Biotech plc's cash, cash equivalents and investments came to $5.1M at the end of fiscal year 2025, against $177.1M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Trinity Biotech plc scores 6/100 among other emerging companies.
Trinity Biotech plc passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, Trinity Biotech plc used $3.10 of operating cash (-$5.9M OCF vs $1.9M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q3 2025.
Cash & Balance Sheet
Trinity Biotech plc held $5.2M in cash as of Q3 2025; long-term debt is not reported for that period.
Not reported for Q3 2025.
Not reported for Q3 2025.
Margins & Returns
None of these metrics is reported for Q3 2025.
Capital Allocation
None of these metrics is reported for Q3 2025.
TRIB Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
TRIB Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2510-K | Q1'2510-Q | Q3'2410-K | Q3'2310-K | Q1'2310-Q | Q3'2210-K | Q3'2110-K | Q3'2010-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $103.3M+73.8% | $94.4M | $59.4M-35.5% | $92.1M-22.5% | $107.1M | $118.9M-8.8% | $130.4M-0.5% | $131.1M-13.6% |
| Current Assets | $41.1M+5.3% | $46.0M | $39.0M-16.3% | $46.7M-35.8% | $57.2M | $72.7M-12.7% | $83.3M+16.7% | $71.4M-17.6% |
| Cash & Equivalents | $5.2M+40.0% | $5.3M | $3.7M-43.9% | $6.6M-74.6% | $10.5M | $25.9M-5.2% | $27.3M+79.4% | $15.2M-49.7% |
| Inventory | $19.4M-2.8% | $23.0M | $19.9M-11.4% | $22.5M-22.7% | $29.1M | $29.1M-3.6% | $30.2M-5.6% | $32.0M+5.5% |
| Accounts Receivable | $16.1M+15.6% | $17.5M | $13.9M-11.8% | $15.8M-2.3% | $15.9M | $16.1M-28.9% | $22.7M+8.0% | $21.0M-14.1% |
| Goodwill | $51.3M+215.6% | $41.8M | $16.3M-53.9% | $35.3M-2.0% | $38.7M | $36.0M+6.3% | $33.9M-22.4% | $43.7M-17.6% |
| Total Liabilities | $138.5M+66.1% | $123.8M | $83.4M-11.6% | $94.3M-20.9% | $91.3M | $119.2M-10.1% | $132.6M+5.0% | $126.4M+17.4% |
| Current Liabilities | $32.1M+113.5% | $25.8M | $15.0M-13.3% | $17.3M-82.7% | $13.9M | $100.5M+271.4% | $27.1M+39.1% | $19.4M+10.5% |
| Non-Current Liabilities | $106.4M+55.6% | $98.0M | $68.3M-11.2% | $76.9M+310.9% | $77.4M | $18.7M-82.3% | $105.6M-1.3% | $106.9M+18.8% |
| Long-Term Debt | N/A | $10.2M | $10.9M | N/A | $12.7M | $13.9M+1230.6% | $1.0M0.0% | $1.0M-99.0% |
| Total Equity | -$35.2M-46.9% | -$29.4M | -$23.9M-1000.6% | -$2.2M-582.1% | $15.8M | -$319K+85.6% | -$2.2M-147.1% | $4.7M-89.3% |
| Retained Earnings | -$79.1M-62.6% | -$57.8M | -$48.6M-82.2% | -$26.7M-312.6% | -$9.1M | $12.6M+18.8% | $10.6M-34.5% | $16.1M-70.8% |
Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments.
TRIB Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
TRIB Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$72.0M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.25), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Trinity Biotech plc TRIB | FY2025 | $43.8M | $1.9M | 4.4% | $5.6M | 26/100 |
| Iridex Corp IRIX | FY2025 | $52.7M | -$4.4M | -8.4% | $15.6M | 50/100 |
| Nortech Systems Inc NSYS | FY2025 | $118.4M | -$252K | -0.2% | $32.4M | 37/100 |
| Adagio Medical Holdings, Inc ADGM | FY2025 | $0 | -$25.1M | N/A | $3.5M | — |
| Pheton Holdings Ltd PTHL | FY2025 | $523K | -$5.1M | N/A | $15.4M | — |
| Ainos, Inc. AIMD | FY2025 | $124K | -$14.8M | N/A | $8.9M | — |
Where Trinity Biotech plc Ranks
Frequently Asked Questions
What is Trinity Biotech plc's annual revenue?
Trinity Biotech plc (TRIB) reported $43.8M in total revenue for fiscal year 2025. This represents a -28.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Trinity Biotech plc's revenue growing?
Trinity Biotech plc (TRIB) revenue declined by 28.9% year-over-year, from $61.6M to $43.8M in fiscal year 2025.
Is Trinity Biotech plc profitable?
Yes, Trinity Biotech plc (TRIB) reported a net income of $1.9M in fiscal year 2025, with a net profit margin of 4.4%.
How much debt does Trinity Biotech plc have?
As of fiscal year 2025, Trinity Biotech plc (TRIB) had $5.1M in cash and equivalents against $20.0M in long-term debt.
What is Trinity Biotech plc's net profit margin?
Trinity Biotech plc (TRIB) had a net profit margin of 4.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Trinity Biotech plc's free cash flow?
Trinity Biotech plc (TRIB) recorded an outflow of $6.0M in free cash flow during fiscal year 2025. This represents a -30.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Trinity Biotech plc's operating cash flow?
Trinity Biotech plc (TRIB) recorded an outflow of $5.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Trinity Biotech plc's total assets?
Trinity Biotech plc (TRIB) had $105.2M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Trinity Biotech plc's capital expenditures?
Trinity Biotech plc (TRIB) invested $88K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Trinity Biotech plc's current ratio?
Trinity Biotech plc (TRIB) had a current ratio of 0.25 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Trinity Biotech plc's return on assets (ROA)?
Trinity Biotech plc (TRIB) had a return on assets of 1.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Trinity Biotech plc's P/E ratio?
Trinity Biotech plc (TRIB) trades at 2.9x earnings, its market capitalization divided by net income of $1.9M net income, FY2025. The market capitalization is $5.6M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Trinity Biotech plc's price-to-sales ratio?
Trinity Biotech plc (TRIB) trades at 0.1x sales, its market capitalization divided by revenue of $43.8M revenue, FY2025. The market capitalization is $5.6M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Trinity Biotech plc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Trinity Biotech plc (TRIB) held $5.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $5.9M over that year. Dividing the one by the other, the reported balance equals about 10 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is Trinity Biotech plc's debt-to-equity ratio negative or not reported?
Trinity Biotech plc (TRIB) has negative shareholder equity of -$72.0M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Trinity Biotech plc's Piotroski F-Score?
Trinity Biotech plc (TRIB) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Trinity Biotech plc's earnings high quality?
For every $1 of reported earnings, Trinity Biotech plc (TRIB) used $3.10 of operating cash (-$5.9M OCF vs $1.9M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Trinity Biotech plc?
Trinity Biotech plc (TRIB) scores 26 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.